Literature DB >> 32511849

Bipolar disorder, COVID-19, and the risk of relapse.

Ravi P Rajkumar1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32511849      PMCID: PMC7300969          DOI: 10.1111/bdi.12947

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   5.345


× No keyword cloud information.
To The Editor, The novel coronavirus disease (COVID‐19) pandemic represents a global health crisis which can directly or indirectly affect the mental health of millions of people around the world. There are certain aspects of this pandemic, and of the measures necessary for its control, which are of particular concern for patients with bipolar disorders, particularly as regards the risk of relapse. First, the course of bipolar disorders is sensitive to factors that can disrupt biological and social rhythms, an effect which is mediated through mechanisms related to circadian rhythm regulation. A number of the measures that have been advocated to curtail the spread of COVID‐19, such as home confinement, social distancing, lockdowns and quarantine, can potentially disrupt both habitual patterns of sleep and wakefulness as well as the number and quality of social contacts and activities. This could have a deleterious influence on the risk of both manic and depressive relapses. Second, there is a close relationship between bipolar disorders and substance use, particularly alcohol use. During the COVID‐19 pandemic, some nations have opted to continue sales of alcohol for home consumption, leading to a potential increase in use in vulnerable individuals. Others have opted to restrict such sales, potentially triggering symptoms of alcohol withdrawal. In patients with bipolar disorder, this could lead to increased symptom severity, as well as adverse outcomes such as suicide. Third, there is evidence of an association between seropositivity for coronaviruses and the risk of mood disorders and suicide. Though the significance of this association is unclear, it may be related to the neurotropic potential of respiratory coronaviruses, or to their ability to provoke a systemic inflammatory reaction, both of which may be associated with mood dysregulation. Other issues of concern in this patient group include the general stresses associated with a disease outbreak, and reduced access to treatment during an epidemic, both of which can trigger a relapse. Further, patients in a manic or hypomanic episode may fail to comply with social distancing or other hygienic measures, placing them at a higher risk of infection. It is of vital importance to assess the impact of these factors on patients with bipolar disorder as the COVID‐19 epidemic unfolds, as its effects are likely to be prolonged and far‐reaching.
  3 in total

Review 1.  Social rhythm therapy-A potentially translatable psychosocial intervention for bipolar disorder.

Authors:  Marie Crowe; Maree Inder; Holly A Swartz; Greg Murray; Richard Porter
Journal:  Bipolar Disord       Date:  2019-09-29       Impact factor: 6.744

Review 2.  Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations.

Authors:  Mark A Frye; Ihsan M Salloum
Journal:  Bipolar Disord       Date:  2006-12       Impact factor: 6.744

3.  Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts.

Authors:  Olaoluwa Okusaga; Robert H Yolken; Patricia Langenberg; Manana Lapidus; Timothy A Arling; Faith B Dickerson; Debra A Scrandis; Emily Severance; Johanna A Cabassa; Theodora Balis; Teodor T Postolache
Journal:  J Affect Disord       Date:  2010-10-27       Impact factor: 4.839

  3 in total
  5 in total

1.  Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the COVID-19 pandemic.

Authors:  Simon Lambrichts; Kristof Vansteelandt; Bo Crauwels; Jasmien Obbels; Eva Pilato; Jonas Denduyver; Katrien Ernes; Pieter-Paul Maebe; Charlotte Migchels; Lore Roosen; Satya Buggenhout; Filip Bouckaert; Didier Schrijvers; Pascal Sienaert
Journal:  Acta Psychiatr Scand       Date:  2021-06-28       Impact factor: 7.734

2.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

3.  The COVID-19 pandemic impact on wellbeing and mental health in people with psychotic and bipolar disorders.

Authors:  Elizabeth Ann Barrett; Carmen Simonsen; Sofie Ragnhild Aminoff; Wenche Ten Velden Hegelstad; Trine Vik Lagerberg; Ingrid Melle; Erlend Mork; Kristin Lie Romm
Journal:  Brain Behav       Date:  2022-04-06       Impact factor: 3.405

4.  Mental health prior to and during the COVID-19 pandemic in individuals with bipolar disorder: Insights from prospective longitudinal data.

Authors:  Katie J S Lewis; Katherine Gordon-Smith; Kate E A Saunders; Clare Dolman; Matthew South; John Geddes; Nick Craddock; Arianna Di Florio; Ian Jones; Lisa Jones
Journal:  Bipolar Disord       Date:  2022-03-28       Impact factor: 5.345

Review 5.  The Relationship between Mental Disorders and the COVID-19 Pandemic-Course, Risk Factors, and Potential Consequences.

Authors:  Agnieszka Markiewicz-Gospodarek; Aleksandra Górska; Renata Markiewicz; Zuzanna Chilimoniuk; Marcin Czeczelewski; Jacek Baj; Ryszard Maciejewski; Jolanta Masiak
Journal:  Int J Environ Res Public Health       Date:  2022-08-04       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.